Urogen Pharma (NASDAQ:URGN) Releases Quarterly Earnings Results, Beats Estimates By $0.01 EPS

Key Points

• Urogen Pharma reported EPS of ($0.47), beating consensus by $0.01, and revenue of $50.96 million versus $44.83 million expected.
• Commercial adoption of ZUSDURI accelerated — Q1 revenue was $29.2M (>100% QoQ) after a permanent J‑code, with unique prescribers rising to 256, repeat prescribers to 103, conversion times improving to ~30–35 days, and payer coverage now above 95%.
• Pipeline momentum continues with an NDA for UGN-103 targeted in H2 2026 (6‑month durability mid‑year), an ongoing phase III for UGN-104, and an IND/Phase I for UGN-501 planned by year‑end, but management declined to provide 2026 sales guidance for ZUSDURI; the company ended Q1 with roughly $140.3M cash and a narrowed net loss of $23.6M.

Urogen Pharma (NASDAQ:URGN - Get Free Report) announced its quarterly earnings data on Wednesday. The company reported ($0.47) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.48) by $0.01, FiscalAI reports. The firm had revenue of $50.96 million during the quarter, compared to analysts' expectations of $44.83 million.

Here are the key takeaways from Urogen Pharma's conference call:

• ZUSDURI delivered $29.2M in Q1 revenue (>100% quarter-over-quarter growth) with the permanent J-code cited as a key catalyst for accelerated utilization.
• Commercial adoption is expanding: unique prescribers rose to 256 (from 102), repeat prescribers to 103 (from 32), PEFs and conversion times improved to ~30–35 days in Q1, and payer coverage now exceeds 95%.
• Pipeline momentum continues: the company plans an NDA for UGN-103 in H2 2026 (6-month durability data mid-year; potential 2027 approval), ongoing phase III for UGN-104, and an IND for UGN-501 with a Phase I start planned by year-end.
• Financials show progress (total Q1 revenue $51M, net loss narrowed to $23.6M, and cash of ~$140.3M), but Q1 SG&A jumped as expected and management declined to provide 2026 sales guidance for ZUSDURI, leaving near-term revenue visibility limited.

Urogen Pharma Price Performance

URGN stock traded up $3.49 during trading on Wednesday, hitting $27.32. 2,024,108 shares of the company traded hands, compared to its average volume of 792,737. The stock's 50-day simple moving average is $20.37 and its 200 day simple moving average is $21.44. The company has a market cap of $1.33 billion, a PE ratio of -8.55 and a beta of 1.58. Urogen Pharma has a 1 year low of $3.42 and a 1 year high of $30.00.

Analyst Ratings Changes

Several research analysts have recently issued reports on the company. Jefferies Financial Group upgraded Urogen Pharma to a "strong-buy" rating in a research note on Friday, April 24th. D. Boral Capital restated a "buy" rating and issued a $33.00 price objective on shares of Urogen Pharma in a research note on Tuesday, March 31st. Weiss Ratings restated a "sell (d-)" rating on shares of Urogen Pharma in a research note on Monday, April 20th. Finally, Oppenheimer restated an "outperform" rating on shares of Urogen Pharma in a research note on Monday, March 2nd. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $34.13.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the stock. Intech Investment Management LLC increased its position in shares of Urogen Pharma by 45.9% in the fourth quarter. Intech Investment Management LLC now owns 22,210 shares of the company's stock valued at $520,000 after buying an additional 6,983 shares in the last quarter. Jacobs Levy Equity Management Inc. purchased a new stake in shares of Urogen Pharma in the third quarter valued at approximately $426,000. Cinctive Capital Management LP purchased a new stake in shares of Urogen Pharma in the fourth quarter valued at approximately $398,000. WINTON GROUP Ltd purchased a new stake in shares of Urogen Pharma in the fourth quarter valued at approximately $309,000. Finally, New York State Common Retirement Fund increased its position in shares of Urogen Pharma by 62.5% in the fourth quarter. New York State Common Retirement Fund now owns 12,737 shares of the company's stock valued at $298,000 after buying an additional 4,900 shares in the last quarter. 91.29% of the stock is currently owned by hedge funds and other institutional investors.

About Urogen Pharma

UroGen Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for uro-oncology and uro-genital diseases. Founded in 2010 and headquartered in Ra'anana, Israel, with offices in New York, UroGen applies its proprietary RTGel® reverse thermal gel delivery platform to create sustained-release formulations designed for in-office use by urologists.

The company's lead product, Jelmyto® (mitomycin gel), received U.S. Food and Drug Administration approval in 2020 for the treatment of adults with low-grade upper tract urothelial cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.